Provectus Biopharmaceuticals Inc.

349 articles with Provectus Biopharmaceuticals Inc.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.
• 

  Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

  1/29/2020

  Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
• 

  Clinical Catch-up from Last Week: June 1-June 7

  6/10/2019

  Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.

• PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10

  7/31/2018

  Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients

• PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING

  7/10/2018

  Provectus announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting, held in Munich, Germany from June 28-29.

• 

  Biotechnology and the Environment: Can Biotech Save the Planet?

  6/26/2018

  Think biotechnology, you probably think cutting-edge development of drugs to treat diseases. Yet in 2007, a U.S. EPA report noted that industrial biotechnology and biobased manufacturing are more efficient, cleaner and make better use of sustainable renewable resources.

• PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE

  6/19/2018

  Provectus today announced that the Indian Patent Office (IPO) has granted the Company’s patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus’ lead investigational oncology drug.

• 

  Former Provectus CEO Used Company Cash for Restaurants, Cosmetic Surgery and More

  12/13/2017

  Craig Dees, CEO of Provectus treated the company as "his own personal piggy bank" by submitting hundreds of falsified records to obtain $3.2M for personal expenses

• Provectus Reestablishes Strategic Advisory Board

  4/21/2017

• Provectus Closes Definitive Financing With PRH Group

  4/4/2017

• Provectus Announces Terms Of Definitive Financing Commitment

  3/24/2017

• Provectus Enters Into Definitive Financing Commitment Term Sheet

  3/20/2017

• Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus

  3/6/2017

• Provectus Provides Information On Rights Offering Deadline

  2/24/2017

• Provectus Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors

  2/23/2017

• Provectus Announces Extension Of Rights Offering

  2/13/2017

• Provectus Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants

  1/31/2017

• Provectus Fires Peter Culpepper as Interim CEO and COO

  12/30/2016

• Provectus Announces Two Poster Presentations On PV-10 For Liver Tumors

  12/22/2016

• Provectus Announces Agreement With POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) To Study Potential Of PV-10 For Pediatric Cancer

  12/8/2016